Education
About Us
Working with TipRanks
Follow Us
Inmune Bio Inc (INMB)
NASDAQ:INMB
INMB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.32 - $12.72
Previous CloseN/A
Volume114.20K
Average Volume (3M)309.40K
Market Cap
$215.92M
Enterprise Value$78.16M
Total Cash (Recent Filing)$35.85M
Total Debt (Recent Filing)$10.44M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Mar 27, 2025EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding26,591,080
10 Day Avg. Volume260,457
30 Day Avg. Volume309,398
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4286.67
Price to Cash Flow (P/CF)-6.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit504.27
Enterprise Value/Ebitda-2.56
Forecast
1Y Price Target
$23.40Price Target Upside181.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Inmune Bio News
PremiumCompany Announcements
INmune Bio Reports Promising Phase I/II Trial Results
PremiumCompany Announcements
Inmune Bio Secures License Agreement for CORDStrom Data
PremiumCompany Announcements
Inmune Bio Completes Phase 2 Trial for CORDStrom---
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsPositive dose-related changes were demonstrated in the cerebrospinal fluid proteome in Alzheimer's disease patients treated with XPro, specifically related to synaptic proteins essential for communication between neurons.
Market OpportunityRecessive dystrophic epidermolysis bullosa (RDEB) could represent a $1B opportunity with potential for premium pricing.
Regulatory SupportThe FDA has indicated during a Type C meeting that the data from the study could support a filing.
Bears Say
Financial PerformanceINmune announced a $13M equity financing, which should extend the runway through the P2 data.
Treatment EffectivenessThe key takeaway from the CORDStrom data was that two infusions of human mesenchymal stem cells showed improvements in itch, a clinically meaningful endpoint known to negatively impact quality of life in RDEB patients.
Trial ChallengesEvaluations of other historical datasets suggest that the size and length of the INMB P2 AD trial provide sufficient power to show an effect.
---
Ownership Overview
17.01% Insiders
4.02% Mutual Funds
6.29% Other Institutional Investors
67.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INMB FAQ
What was Inmune Bio Inc’s price range in the past 12 months?
Inmune Bio Inc lowest stock price was $4.32 and its highest was $12.72 in the past 12 months.
What is Inmune Bio Inc’s market cap?
Inmune Bio Inc’s market cap is $215.92M.
When is Inmune Bio Inc’s upcoming earnings report date?
Inmune Bio Inc’s upcoming earnings report date is Mar 27, 2025 which is tomorrow.
How were Inmune Bio Inc’s earnings last quarter?
Inmune Bio Inc released its earnings results on Oct 31, 2024. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.507 by -$0.093.
Is Inmune Bio Inc overvalued?
According to Wall Street analysts Inmune Bio Inc’s price is currently Undervalued.
Does Inmune Bio Inc pay dividends?
Inmune Bio Inc does not currently pay dividends.
What is Inmune Bio Inc’s EPS estimate?
Inmune Bio Inc’s EPS estimate is -0.55.
How many shares outstanding does Inmune Bio Inc have?
Inmune Bio Inc has 26,591,080 shares outstanding.
What happened to Inmune Bio Inc’s price movement after its last earnings report?
Inmune Bio Inc reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.507. Following the earnings report the stock price went up 3.248%.
Which hedge fund is a major shareholder of Inmune Bio Inc?
Currently, no hedge funds are holding shares in INMB
---
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.40 (181.93% Upside)
$23.40 (181.93% Upside)
Blogger Sentiment
Neutral
INMB Sentiment 50%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 10.4%
Last 30 Days ▼ 10.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.96%
12-Months-Change
Fundamentals
Return on Equity
-98.97%
Trailing 12-Months
Asset Growth
-15.82%
Trailing 12-Months
Company Description
Inmune Bio Inc
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
---
INMB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, with significant achievements in clinical trial progress and financial stability outweighing the increased net loss and R&D expenses. The company's strategic focus on advancing its Alzheimer's and cancer programs shows promise for future developments.Read More>---
INMB Stock 12 Month Forecast
Average Price Target
$23.40
▲(181.93% Upside)
Technical Analysis
Cassava Sciences
―
Axon Enterprise
―
Aurinia Pharmaceuticals
―
Anavex Life Sciences
―
Annovis Bio
―
Best Analysts Covering INMB
1 Year
1 Year Success Rate
8/20 ratings generated profit
1 Year Average Return
-5.34%
reiterated a buy rating last month
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -5.34% per trade.
---